Viking Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9920 Pacific Heights Blvd Ste 350, San D...Phone Number
(858) 704-4660Website
www.vikingtherapeutics.comRevenue
$124.7 MillionStock Symbol
VKTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Viking Therapeutics
Viking Therapeutics, founded in 2012, is a clinical-stage biopharmaceutical company focused on developing novel, orally available therapies for metabolic and endocrine disorders. The company specializes in research and development of innovative therapeutics targeting metabolism to improve patient outcomes. Viking Therapeutics has multiple clinical programs in its portfolio, including treatments for lipid and metabolic disorders, X-linked adrenoleukodystrophy, and solutions for patients recovering from hip fractures. The company also has earlier-stage programs targeting metabolic diseases and anemia. Viking Therapeutics holds exclusive worldwide rights to a portfolio of therapeutic programs based on small molecules licensed from other pharmaceutical companies. The company is publicly traded and maintains operations across multiple locations in North America.Explore more
Viking Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Viking Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Viking Therapeutics is spiking on competitors!
Earning: See what the market has to say on Viking Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Viking Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Viking Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Viking Therapeutics launches new products
Funding: Get notified immidiatlly once Viking Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Viking Therapeutics
Viking Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Viking Therapeutics
Find 3 more new buyers
Compare Similar Companies to Viking Therapeutics
Compare insights from companies similar to Viking Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Viking Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Viking Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Viking Therapeutics.
Viking Therapeutics financials insights
Gather financial insights about Viking Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$24M
Viking Therapeutics Tech Stack
A closer look at the technologies used by Viking Therapeutics
Most Recent Scoops
Open Position
Open Position
Person-Based
Person-Based
Medical Research
Open Position
Viking Therapeutics News & Media
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage...Viking Therapeutics (VKTX) Soars Higher — Medicare Could Hold The Answer
Viking Therapeutics extended its winning streak to an 8th consecutive day on Tuesday, as investors gobbled up shares amid the growing appetite for the weight loss market, thanks to Medicare’s beginning...Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.Does Viking Therapeutics (VKTX) New CMO Hire Reveal a Deeper Metabolic Ambition?
In June 2026, Viking Therapeutics appointed Hubert C. Chen, M.D., as chief medical officer to lead its clinical, medical, and regulatory functions under CEO Brian Lian. Dr. Chen’s background in obesity, type 2 diabetes, and regulatory strategy for successful drug approvals directly aligns with Viking’s focus on VK2735 and broader metabolic programs. Now we’ll explore how Dr. Chen’s arrival as chief medical officer could shape Viking Therapeutics’ investment narrative around obesity...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Viking Therapeutics
Sign Up For FreeTo access detailed company insights
Viking Therapeutics, founded in 2012, is a clinical-stage biopharmaceutical company focused on developing novel, orally available therapies for metabolic and endocrine disorders. The company specializes in research and development of innovative therapeutics targeting metabolism to improve patient outcomes. Viking Therapeutics has multiple clinical... Read More
